A Single-Dose, Randomized, Open-Label, 2-Treatment, 3-Period, 3-Sequence, 3-Way Crossover, Partial Replicate, Oral Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block

Trial Profile

A Single-Dose, Randomized, Open-Label, 2-Treatment, 3-Period, 3-Sequence, 3-Way Crossover, Partial Replicate, Oral Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Budesonide/formoterol (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Sponsors Intech Biopharm
  • Most Recent Events

    • 04 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top